Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mesoderm induction early response protein 2 (MIER2) is a protein-coding gene and member of the MIER family of transcriptional regulators[3][7][8]. MIER2 functions primarily as a transcriptional co-repressor by binding to histone deacetylases (HDACs) and participating in chromatin remodeling, resulting in repression of gene transcription by RNA polymerase II[1][3][7][8]. It is found in both the cytoplasm and nucleus, acting in complex with other proteins to regulate gene expression[1][8]. Key roles for MIER2 include the regulation of neuronal genes, in part by interaction with the REST repressor complex[1]. It has not been directly implicated as a drug target nor is it currently linked to major therapeutic modalities. MIER2 is associated with at least one disorder—De Quervain disease—but broader disease implications have not been firmly established[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesoderm induction early response protein 2 (MIER2).